Verici Dx Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Public

  • Employees
  • 22

Employees

  • Stock Symbol
  • VRCI

Stock Symbol

Verici Dx General Information

Description

Verici Dx PLC is the development of prognostic and diagnostic tests for kidney transplant patients. It is a commercial stage diagnostics company, transforming the outcomes of kidney transplants through a complementary suite of proprietary, edge tests. These form a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. It has developed a suite of blood-based tests for kidney transplant patients. The group has one division being the development of prognostic and diagnostic tests for kidney transplant patients. The company's products are Tutivia, Clarava, Protega. The company's services are Next Generation Sequencing Services, Bioinformatics and Data Science Services.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 393 Nichol Mill Lane
  • Suite 200
  • Franklin, TN 37067
  • United States
+1 (833)
Primary Industry
Laboratory Services (Healthcare)
Stock Exchange
LON
Vertical(s)
Corporate Office
  • 393 Nichol Mill Lane
  • Suite 200
  • Franklin, TN 37067
  • United States
+1 (833)

Verici Dx Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Verici Dx Stock Performance

As of 18-Nov-2026, Verici Dx’s current market cap is $16.3M with 6.66B shares.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.3M 6.66B 10.1M

Verici Dx Financials Summary

As of 30-Jun-2026, Verici Dx has a trailing 12-month revenue of $3.52M.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 8,271 14,593 5,288 16,471
Revenue 3,522 3,664 3,339 1,013
EBITDA (7,315) (6,404) (5,405) (8,038)
Net Income (7,877) (6,933) (5,874) (8,734)
Total Assets 8,152 7,940 7,492 7,443
Total Debt 772 197 371 540
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Verici Dx Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Verici Dx‘s full profile, request access.

Request a free trial

Verici Dx Patents

Verici Dx Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024372435-A1 Pre-transplant blood based transcriptomic signatures for prediction of kidney transplant rejection Pending 30-Oct-2023
EP-4802101-A1 Pre-transplant blood based transcriptomic signatures for prediction of kidney transplant rejection Pending 30-Oct-2023
WO-2025093575-A1 Pre-transplant blood based transcriptomic signatures for prediction of kidney transplant rejection Inactive 30-Oct-2023
AU-2023378357-A1 Method and kits for a transcriptomic signature with empirically derived algorithm correlated to the presence of acute rejection on kidney biopsy in transplant recipient blood Pending 09-Nov-2022
EP-4616002-A1 Method and kits for a transcriptomic signature with empirically derived algorithm correlated to the presence of acute rejection on kidney biopsy in transplant recipient blood Pending 09-Nov-2022 C12Q1/6883
To view Verici Dx’s complete patent history, request access »

Verici Dx Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Verici Dx Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Verici Dx‘s full profile, request access.

Request a free trial

Verici Dx ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Healthcare

Industry

Rank

Percentile

Medical Services

Subindustry

Rank

Percentile

To view Verici Dx’s complete esg history, request access »

Verici Dx FAQs

  • When was Verici Dx founded?

    Verici Dx was founded in 2020.

  • Where is Verici Dx headquartered?

    Verici Dx is headquartered in Franklin, TN.

  • What is the size of Verici Dx?

    Verici Dx has 22 total employees.

  • What industry is Verici Dx in?

    Verici Dx’s primary industry is Laboratory Services (Healthcare).

  • Is Verici Dx a private or public company?

    Verici Dx is a Public company.

  • What is Verici Dx’s stock symbol?

    The ticker symbol for Verici Dx is VRCI.

  • What is the current market cap of Verici Dx?

    The current market capitalization of Verici Dx is $16.3M.

  • What is Verici Dx’s current revenue?

    The trailing twelve month revenue for Verici Dx is $3.52M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process